论文部分内容阅读
目的:探讨超高龄弥漫大B细胞淋巴瘤患者的治疗方案。方法:回顾从2009至2014年收治的5例超高龄弥漫大B细胞淋巴瘤患者的临床资料,分析患者的治疗方案、疗效、耐受性及总生存期(OS)。结果:5例患者分期为Ⅲ至IV期,入院时PS评分为1~2分,采用了以R-mini CHOP、R-CHOP等基础的方案,一线治疗后2例达到了CR,1例达到PR,1例SD,1例PD,2例进行了二线化疗,其中1例达到了CR,1例PD。5例患者通过一线化疗均缓解了症状,在治疗过程中没有出现严重不良反应。截止到随访结束,有3例患者仍然存活,有2例患者死亡,总生存期最长达到了75个月。结论:通过个体化的治疗,超高龄弥漫大B细胞淋巴瘤患者可以达到满意的治疗效果。
Objective: To investigate the treatment of patients with super-large diffuse large B-cell lymphoma. Methods: The clinical data of 5 patients with super large B-cell lymphoma from 2009 to 2014 were retrospectively analyzed. The treatment, efficacy, tolerability and overall survival (OS) were analyzed. Results: The 5 patients were stage Ⅲ to IV. The PS score was 1 to 2 at admission. The basic protocols of R-mini CHOP and R-CHOP were used. After first-line treatment, 2 cases achieved CR and 1 case achieved PR, 1 case of SD, 1 case of PD, 2 cases were second-line chemotherapy, including 1 case of CR, 1 case of PD. Five patients were relieved of symptoms by first-line chemotherapy, no serious adverse reactions in the course of treatment. By the end of follow-up, three patients survived, two died, and the longest overall survival reached 75 months. Conclusion: Through individualized treatment, patients with ultra-advanced diffuse large B-cell lymphoma can achieve satisfactory therapeutic effect.